Navigation Links
Potential treatment for deadly E. coli disease

A potential life-saving treatment for severe E. coli food poisoning outbreaks developed more than a decade ago hasn't gone forward into clinical trials because of lack of commercial interest.

University of Adelaide researchers produced a "designer" probiotic bacterium which binds and neutralises the toxin produced by E. coli, which causes life-threatening attack on the kidneys and blood vessels.

The team of scientists Dr Adrienne Paton, Associate Professor Renato Morona and Professor James Paton showed that mice infected with a highly virulent strain of E. coli were completely protected by the probiotic bacterium.

The research was published in the prestigious journal Nature Medicine in 2000 and generated ongoing interest from the scientific and medical community but the commercial sector hasn't taken up its development for progress into clinical trials in humans.

"Severe E. coli food poisoning outbreaks such as that currently occurring in Europe are becoming increasingly common," said Professor Paton, Director, Research Centre for Infectious Diseases at the University of Adelaide.

"They have the potential to cause widespread disease and many patients develop life-threatening complications including kidney failure.

"The probiotic bacterium could be produced cheaply on a large scale. However, in spite of on-going attention from the scientific and medical community, there has been a lack of interest from the commercial sector in taking this product forward into clinical trials.

"If this had been done, and the probiotic had been proven to be safe and efficacious in humans, it could have been deployed during the current European outbreak. This would undoubtedly have saved lives, as well as millions of dollars in current and future health care costs."

The researchers engineered a harmless bacterium to mimic binding receptors for the potentially fatal Shiga toxin on its surface.

Professor Paton said after diagnosis of E. coli infection there was a window of opportunity for therapeutic intervention before kidneys started to fail. Antibiotics are not used because they can increase the amount of toxin released in the gut.


Contact: Professor James Paton
University of Adelaide

Related biology news :

1. Estimating landfill gas potential
2. CDC assesses potential human exposure to prion diseases
3. Scientists find new class of compounds with great potential for research and drug development
4. Liquid smoke from rice shows potential health benefits
5. CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research
6. Discovery demonstrates potential MS therapy could kill brain cells
7. GW researchers reveal 18 novel subtype-dependent genetic variants for autism spectrum disorders and identify potential genetic markers for diagnostic screening
8. Satellite tracking of sea turtles reveals potential threat posed by manmade chemicals
9. Viral replicase points to potential cancer therapy
10. School energy audits find millions in potential energy savings
11. A diabetes drug, sitagliptin, also has a potential to prevent diabetes
Post Your Comments:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology: